Minerva Neurosciences (NASDAQ:NERV – Get Free Report) had its price target decreased by analysts at HC Wainwright from $11.00 to $7.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 186.89% from the company’s previous close.
Separately, StockNews.com downgraded shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Friday, February 23rd.
Get Our Latest Stock Analysis on NERV
Minerva Neurosciences Stock Up 1.7 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.31). As a group, sell-side analysts forecast that Minerva Neurosciences will post -3.57 earnings per share for the current year.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Featured Stories
- Five stocks we like better than Minerva Neurosciences
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- What is a Death Cross in Stocks?
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.